Thanks, Paul. Consolidated total revenue for the second quarter of 2023 was $368.8 million, a decrease of 6% compared to $392.2 million in the prior year period. The decrease was primarily driven by our Infrastructure segment and to a lesser extent, our Spectrum segment. Net loss attributable to common stockholders for the second quarter of 2023 was $10.5 million or $0.13 per share compared to a net loss of $13.6 million or $0.18 per share in the prior year period. Total adjusted EBITDA was $16.5 million in the second quarter of 2023, an increase from $12.1 million in the prior year period. The increase was primarily driven by the Life Sciences, Infrastructure and Spectrum segments, which was partially offset by the elimination of equity method income from our investment in HMN, which was sold in March of 2023. At Infrastructure, revenue decreased 5.2% to $362.4 million from $382.1 million in the prior year quarter. As discussed earlier, this decrease was primarily driven by the timing and size of projects at the steel fabrication business and lower revenue at DBMG's maintenance and repair business, which was partially offset by an increase in revenue of Banker Steel due to timing and size of projects and backlog. Infrastructure adjusted EBITDA for the second quarter of 2023 increased to $23.5 million from $20.9 million in the prior year period. The increase was primarily driven by timing of higher margin projects at the steel fabrication business. This was partially offset by lower contributions in the maintenance and repair business and Banker Steel due to timing and size of projects, as well as an increase in SG&A. As of June 30, 2023, reported backlog and adjusted backlog, which takes into consideration awarded but not yet signed contracts was $1.5 billion compared to $1.8 billion at the end of 2022. As Avie explained earlier, we continue to see meaningful opportunities in the market and DBM remains focused on converting those opportunities into backlog. DBMG ended the quarter with $234.4 million of debt, which is a decrease of $8.6 million from year-end 2022 driven by normal debt amortization payments and a partial note repayment and was offset in part by an increase in the credit facility. At Life Sciences, the decrease in adjusted EBITDA losses was primarily due to Pansend's net carrying amount of its investment in MediBeacon being zero, which resulted in no additional losses being recognized in our equity investment in MediBeacon in the current period, as well as the decrease in SG&A expense at R2. At Spectrum, revenue was $5.7 million, a decrease of $3.4 million compared to the second quarter of 2022, primarily driven by the elimination in advertising revenues at Azteca, which ceased operations at the end of 2022. This was partially offset by an increase in station revenues, which launched new markets and networks with its customers in the current period. Spectrum delivered adjusted EBITDA of $800,000 in the second quarter compared to adjusted EBITDA of $400,000 in the prior year quarter. The increase was primarily driven by the elimination of networks EBITDA losses in the comparable period as a result of the termination of network and an increase in revenues at station group, which was partially offset by an increase in salaries and benefits. Non-operating corporate adjusted EBITDA losses were $3.4 million for the second quarter of 2023, which was consistent with prior year. At the end of the second quarter, the company had $28.8 million of cash and cash equivalents compared to $80.4 million as of December 31, 2022. On a standalone basis, as of June 30, 2023, the corporate segment had cash and cash equivalents of $9.5 million compared to $9.1 million at the end of 2022. As mentioned in the previous call, the cash balance at year-end was elevated due to a temporary reduction in working capital as a result of receivables collected prior to the end of the year. As of June 30, 2023, INNOVATE had total principal outstanding indebtedness of $749.7 million, up $24.4 million from $725.3 million at the end of 2022, driven primarily by Corporate's new unsecured note with CGIC and R2's additional borrowing from Lancer Capital, which was off -- which was partially offset by Infrastructure's principal payments and Corporate's net decrease in the credit line. Additionally, Spectrum reached a short-term extension on its respective debt while we work on a longer-term solution over the next few months. Subsequent to the end of the quarter, we also borrowed an additional $7 million on the credit line. We recognize that liquidity remains tight as we work to build value in each of the three segments and explore various strategic options to address liquidity in the capital structure. Before I turn the call over to the operator, I'd like to acknowledge Wayne Barr's many contributions to INNOVATE as CEO over the past several years. We were all fortunate to have known and worked with Wayne. He was an excellent leader and a tremendous person that we all miss dearly. On behalf of INNOVATE, I'd like to extend our condolences to Wayne's family and friends. With that, operator, we'd now like to open up the call for questions.